Login / Signup

Risk of Lichen Sclerosus and Lichen Planus in Patients Receiving Immune Checkpoint Inhibitors.

Ahmad AlharbiAttiah KhobraniAfnan NoorWaad AlghamdiAbdulmalik AlotaibiMohammed A AlnuhaitAbdul Haseeb
Published in: International journal of environmental research and public health (2022)
There have been published case reports for these adverse events. Healthcare providers should be aware of the possibility of lichen sclerosis and lichen planus developing in patients receiving ICIs which could necessitate hospitalization or discontinuation. Regulatory agencies are advised to monitor the risks as a potential safety signal.
Keyphrases
  • healthcare
  • human health
  • case report
  • transcription factor
  • risk assessment
  • health insurance
  • affordable care act